Inactive Instrument
Abliva AB Stock OTC Markets
Stocks
NEVPF
SE0002575340
Biotechnology & Medical Research
OTC Markets Traded| 1 day | -6.67% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 59 | 2014-01-09 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | 60 | 2023-01-31 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 50 | 2015-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 2017-11-05 | |
| Director/Board Member | 66 | 2017-04-26 | |
David Bejker
BRD | Director/Board Member | 51 | 2017-04-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.67% | -6.67% | - | - | 76M | |
| -0.50% | -3.61% | +71.05% | +126.22% | 56.71B | |
| -2.45% | -7.83% | +63.92% | +83.15% | 51.3B | |
| +3.27% | +8.91% | +21.21% | +486.76% | 25.26B | |
| -0.81% | -0.42% | -16.24% | -12.47% | 23.65B | |
| +3.93% | +3.35% | +43.09% | -2.47% | 18.69B | |
| -0.38% | +0.72% | +37.62% | -26.13% | 17.71B | |
| +2.34% | +12.50% | +224.02% | +380.99% | 17.7B | |
| -0.92% | +1.58% | +35.79% | - | 14.26B | |
| -1.70% | +3.98% | +28.96% | +190.57% | 14.1B | |
| Average | -0.29% | +4.02% | +56.60% | +153.33% | 26.6B | |
| Weighted average by Cap. | +0.00% | +2.20% | +57.71% | +143.68% |
Employees
6
Choose MarketScreener 
